MRNA (Moderna) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


MRNA Moderna Inc MRNA
60 GF Score
Price $60.55
GF Value $22.94
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Moderna Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Moderna's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

MRNA vs INCY, ROIV, JAZZ: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Moderna's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Moderna's Margin of Safety % (DCF Earnings Based) falls into.


MRNA
60GF Score
Moderna Inc MRNA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Moderna (MRNA) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of $60.55 is trading 163.9% above its estimated GF Value™ of $22.94. GuruFocus considers Moderna to be Significantly Overvalued.

Key valuation signals for MRNA:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $22.94 vs. price of $60.55 (163.9% above fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the MRNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
60GF Score

Get the complete analysis for MRNA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$60.55
Price
$22.94
GF Value